Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 1,200 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,200 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $47.76, for a total value of $57,312.00. Following the sale, the director now directly owns 359,646 shares of the company’s stock, valued at $17,176,692.96. This represents a 0.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Down 3.7 %

Pro-Dex stock traded down $1.74 during midday trading on Tuesday, reaching $45.00. The stock had a trading volume of 15,511 shares, compared to its average volume of 31,039. The company has a fifty day moving average price of $48.12 and a two-hundred day moving average price of $32.49. Pro-Dex, Inc. has a 12 month low of $16.18 and a 12 month high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $146.66 million, a P/E ratio of 29.22 and a beta of 0.56.

Analysts Set New Price Targets

PDEX has been the topic of a number of research analyst reports. Ascendiant Capital Markets increased their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

Institutional Investors Weigh In On Pro-Dex

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its stake in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the last quarter. FMR LLC lifted its stake in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after acquiring an additional 1,028 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after acquiring an additional 3,067 shares in the last quarter. Finally, Bard Associates Inc. raised its holdings in shares of Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. Institutional investors own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.